← All trials
NCT03645109
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 4, 2018
- Primary completion
- Sep 29, 2019
- Completion date
- Dec 20, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Antiguo Hospital Civil de Guadalajara Fray Antonio AlcaldeLead sponsor
- Hospital Civil Juan I. MenchacaSponsor investigator
- Antiguo Hospital Civil de Guadalajara Fray Antonio AlcaldeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.